GSKs-malaria-vaccine-candidate-shows-promise-in-Phase-3-trial
GSK’s malaria vaccine candidate shows promise in Phase 3 trial
According to the results of a large-scale Phase 3 trial, the vaccine candidate RTS,S, showed efficient at protecting young children and infants from clinical malaria up to 18 months after vaccination. ...
Tags: GSK, malaria vaccine, malaria, RTS, S, clinical trial...
October 8, 2013
Pacritinib-to-be-tested-in-a-late-stage-trial-as-a-treatment-for-myelofibrosis
Pacritinib to be tested in a late-stage trial as a treatment for myelofibrosis
Cell Therapeutics announced a late-stage trial of pacritinib as a treatment for a blood disorder called myelofibrosis. Pacritinib will be compared to the best available treatment for myelofibrosis, Jakafi....
Tags: Pacritinib, Cell Therapeutics, myelofibrosis, clinical trial, treatment...
October 8, 2013
Additional-data-from-Talimogene-melanoma-trial
Additional data from Talimogene melanoma trial
Amgen’s Talimogene laherparepvec, a novel oncolytic immunotherapy shows promising results in patients with unresected stage IIIB, IIIC or IV melanoma in a Phase 3 trial....
Tags: talimogene, melanoma, oncolytic immunotherapy, clinical trial, Amgen...
October 3, 2013
Neural-stem-cells-as-a-treatment-for-spinal-cord-injury
Neural stem cells as a treatment for spinal cord injury
StemCells Inc.' received authorization from the FDA for its Investigational New Drug application for clinical testing of human neural stem cells (HuCNS-SC) as a treatment for chronic spinal cord injury. Phase 1/2 clinical trial is on its way....
Tags: stem cells, neural, spinal cord injury, clinical trial, treatment...
October 2, 2013
New-hope-for-patients-with-progressive-thyroid-cancer
New hope for patients with progressive thyroid cancer
Two recent clinical trials have shown that patients with progressive thyroid cancer can benefit from the treatment with two drugs, a kinase inhibitor - sorafenib and BRAFV600E inhibitor - vemurafenib, that are already approved for the treatment of other types of cancer....
Tags: thyroid cancer, progressive, sorafenib, vemurafenib, kinase inhibitor, BRAFV600E, mutation, inhibitor, PTC, treatment...
October 1, 2013
T-DM1-drug-beneficial-for-patients-with-advanced-HER2-positive-breast-cancer
T-DM1 drug beneficial for patients with advanced HER2 positive breast cancer
The results of the Phase 3 TH3RESA trial show that T-DM1, a conjugated monoclonal antibody in which trastuzumab is combined with a cell-killing drug emtansine (DM1), significantly improves the length of time before the disease worsens in HER2 positive breast cancer pati...
Tags: T-DM1, breast cancer, advanced breast cancer, HER2 positive, combination drug, trastuzumab, emtansine, clinical trial...
September 29, 2013
The-results-of-Phase-12-study-of-Takedas-norovirus-vaccine-candidate
The results of Phase 1/2 study of Takeda’s norovirus vaccine candidate
The intramuscular bivalent (GI/GII) norovirus vaccine candidate in healthy adults who were challenged with the most commonly occurring norovirus that causes gastroenteritis showed promise in a Phase 1/2 study....
Tags: Takeda, vaccine, norovirus, gastroenteritis, clinical trial...
October 8, 2013
Humira-as-a-treatment-for-hidradenitis-suppurativa-the-results-of-Phase-2-trial
Humira as a treatment for hidradenitis suppurativa- the results of Phase 2 trial
According to the results of Phase 2 clnical trial, Humira induced a significant response rate, compared to placebo, in adult patients with moderate-to-severe hidradenitis suppurativa (HS). The drug will be further evaluated in Phase 3 trials. ...
Tags: Humira, AbbVie, hidradenitis suppurativa, clinical trial...
October 5, 2013
Cediranib-beneficial-for-women-with-recurrent-ovarian-cancer
Cediranib beneficial for women with recurrent ovarian cancer
The results of a Phase 3 trial show that cediranib, a tyrosine kinase inhibitor of cell signalling process involved in formation of tumor blood vessels, improves survival in women with ovarian cancer that has recurred after platinum-based chemotherapy....
Tags: cediranib, tyrosine kinase inhibitor , clinical trial, ovarian cancer...
October 3, 2013
Tumor-molecular-profiling-offers-hope-to-patients-with-difficult-to-treat-cancers
Tumor molecular profiling offers hope to patients with difficult-to-treat cancers
Two recent studies demonstrated the potential of tumor molecular profiling in patients with cancers of unknown primary (CUP) and rarer and refractory cancers. It provided oncologists with critical information to help them select optimal treatment,which resulted in clin...
Tags: tumor, molecular profiling, difficult-to-treat cancers, cancer of unknown primary, CUP, rare cancer, refractory, cancer, optimal, treatment...
October 2, 2013
Promising-data-from-the-Phase-3-study-of-Erbitux-in-metastatic-colorectal-cancer
Promising data from the Phase 3 study of Erbitux in metastatic colorectal cancer
Merck Serono’s Erbitux (cetuximab) plus FOLFIRI, compared to bevacizumab plus FOLFIRI, has shown a clinically relevant improvement (7.5 month increase in median overall survival) as first-line treatment in metastatic colorectal cancer in patients with RAS wild-typ...
Tags: Erbitux, cetuximab, clinical trail, metastatic, colorectal cancer, Merck, cancer therapy...
September 30, 2013
Novo-Nordisks-type-2-diabetes-therapy-successful-in-Phase-3-trial
Novo Nordisk’s type 2 diabetes therapy successful in Phase 3 trial
The data from DUALT 1 trial show that an investigational therapy IDegLira [Tresiba (insulin degludec)/Victoza (liraglutide injection)] achieved statistically significant greater reduction in blood sugar levels compared to either of the two drugs alone in adults with typ...
Tags: Novo Nordisk, type 2 diabetes, DUALT 1 trial, IDegLira, Tresiba, insulin degludec, Victoza, liraglutide, combination...
September 28, 2013
MOST VIEWED

HOME | ABOUT | PRIVACY POLICY | TERMS & CONDITIONS | ADVERTISE | CONTACT
All rights reserved drugdiscovery.com 2013